A PYMNTS Company

US: Supreme Court pay-for-delay ruling is just the beginning

By  |  March 27, 2013

As the US Supreme Court readies to officially rule on the so-called pay-for-delay schemes used by brand name drug companies to keep the often cheaper generic forms off the shelves, analysts are reportedly expecting ongoing complexities to emerge from the ruling. Further, the ruling will likely lead to more litigation to contest the deals by both the Federal Trade Commission and private parties. The Federal Trade Commission maintains that the pay-for-delay deals violate antitrust law and prevent consumers from having access to less expensive medications. Analysts are torn as to which way the Court is likely to rule.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Thomson Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.